Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation.

Analysis of long-term follow-up for 54 patients with delayed graft function showed a highly significant association between day 1 or 3 serum ACY-1 and dialysis-free survival, mainly associated with the donor–brain–dead transplant type.

also in 132,142 other papers

When non-DGF patients from the larger cohort 2 were categorized on the basis of creatinine reduction ratio (CRR=(day 0 creatinine minus day 7 creatinine)/day 0 creatinine), 17 , 22 significant differences in day 1 serum ACY-1 ( Figure 4c ) between patients categorized as slow graft function (CRR<0.7 ) and immediate graft function (CRR⩾0.7) were seen with an increasing trend from immediate graft function to slow graft function to DGF, demonstrating a relationship between the rate of graft function improvement and ACY-1.

also in 63,971 other papers